


**Product Name** : LY2157299  
**Cat. No.** : PC-43407  
**CAS No.** : 700874-72-2  
**Molecular Formula** : C<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O  
**Molecular Weight** : 369.4192  
**Target** : TGF beta Receptor (TGFBR)  
**Solubility** : DMSO: ≥ 47 mg/mL



## Biological Activity

LY2157299 (Galunisertib) is a potent, specific inhibitor of TGF- $\beta$  receptor I kinase ((**TGF- $\beta$ RI**) with IC<sub>50</sub> of 56 nM. LY2157299 (Galunisertib) inhibits TGF- $\beta$ -mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner, stimulates hematopoiesis from primary MDS bone marrow specimens.

LY2157299 (Galunisertib) ameliorates anemia in a TGF- $\beta$  overexpressing transgenic mouse model of bone marrow failure. LY2157299 (Galunisertib) displays significant antitumor activity against both Calu6 and MX1 xenografts in mice.

## References

- Zhou L, et al. *Cancer Res.* 2011 Feb 1;71(3):955-63.  
Yoon JH, et al. *EMBO Mol Med.* 2013 Nov;5(11):1720-39.  
Bhola NE, et al. *J Clin Invest.* 2013 Mar;123(3):1348-58.  
Rodon J, et al. *Clin Cancer Res.* 2015 Feb 1;21(3):553-60.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com